On Demand Activities
0.50 hr(s) | CME , MOC
Specialty: Oncology , Gynecology
Therapeutic Area(s): Oncology , Gynecology
Release Date: April 30, 2020
Expiration Date: April 29, 2021
Location: Internet Activity Enduring Material
In this activity, experts in oncology discuss current evidence and clinical insights on the evolving role of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in the frontline and recurrent maintenance settings in patients with ovarian cancer.